Strategy Asset Managers LLC acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 57,650 shares of the medical equipment provider’s stock, valued at approximately $2,115,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Parnassus Investments CA acquired a new position in Hologic in the third quarter worth approximately $277,062,000. Capital World Investors acquired a new position in Hologic in the second quarter worth approximately $312,441,000. HealthCor Management L.P. acquired a new position in Hologic in the second quarter worth approximately $76,604,000. Columbus Circle Investors acquired a new position in Hologic in the second quarter worth approximately $54,511,000. Finally, Vanguard Group Inc. grew its position in Hologic by 4.2% in the second quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock worth $1,340,850,000 after buying an additional 1,200,825 shares during the last quarter. Institutional investors and hedge funds own 96.41% of the company’s stock.
Shares of Hologic, Inc. (NASDAQ:HOLX) traded up $1.67 on Tuesday, reaching $40.64. 4,259,600 shares of the company traded hands, compared to its average volume of 2,743,232. The company has a market cap of $10,723.51, a P/E ratio of 19.29, a PEG ratio of 1.88 and a beta of 0.93. Hologic, Inc. has a 12-month low of $35.76 and a 12-month high of $46.80. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.78.
Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, topping the consensus estimate of $0.49 by $0.01. The firm had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The business’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.52 EPS. equities research analysts forecast that Hologic, Inc. will post 2.12 EPS for the current year.
Several research firms have issued reports on HOLX. Zacks Investment Research upgraded shares of Hologic from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Needham & Company LLC reiterated a “buy” rating and set a $50.00 price objective on shares of Hologic in a research report on Friday, November 3rd. Barclays PLC reiterated an “overweight” rating and set a $53.00 price objective (up from $50.00) on shares of Hologic in a research report on Monday, July 17th. BidaskClub cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, Bank of America Corporation reiterated a “neutral” rating and set a $48.00 price objective (up from $44.00) on shares of Hologic in a research report on Friday, July 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $47.54.
In other news, Director Lawrence M. Levy sold 7,138 shares of the business’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $37.38, for a total transaction of $266,818.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Lawrence M. Levy sold 9,596 shares of the business’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total transaction of $353,228.76. The disclosure for this sale can be found here. Insiders sold a total of 25,667 shares of company stock worth $969,299 in the last quarter. Insiders own 0.79% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://sportsperspectives.com/2017/11/14/strategy-asset-managers-llc-invests-2-12-million-in-hologic-inc-holx.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.